Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection

International Journal for Parasitology

Volumn 42, Issue 6, 2012, Pages 535-548

  Offeddu, Vittoria ^a   Thathy, Vandana ^b   Marsh, Kevin ^b,c   Matuschewski, Kai ^a,d  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Antibodies; Liver stages; Malaria; Plasmodium; Protection; Sero epidemiology; Sporozoites; T cell epitopes

Indexed keywords

MALARIA VACCINE;

ANTIBODY; BLOOD; EPIDEMIOLOGY; HEMOPARASITE; IMMUNE RESPONSE; MALARIA; MOSQUITO; PATHOGEN;

AMINO TERMINAL SEQUENCE; ANOPHELES; ANTIBODY SPECIFICITY; ANTIBODY TITER; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CODON; COHORT ANALYSIS; HEPATITIS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; LYMPHOCYTE DEPLETION; MALARIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM FALCIPARUM; PREVALENCE; REVIEW; SEQUENCE HOMOLOGY; SEROCONVERSION; SEROEPIDEMIOLOGY; SPOROZOITE;

HUMANS; INCIDENCE; LIVER; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SPOROZOITES;

ANOPHELES (GENUS); EUKARYOTA; PLASMODIUM (APICOMPLEXA); PLASMODIUM FALCIPARUM;

EID: 84861657261     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.03.011     Document Type: Review

References (146)

1. Achidi E.A., Perlmann H., Salimonu L.S., Perlmann P., Walker O., Asuzu M.C. A longitudinal study of seroreactivities to Plasmodium falciparum antigens in Nigerian infants during their first year of life. Acta Trop. 1995, 59:173-183.
2. Achidi E.A., Salimou L.S., Asuzu M., Berzins K., Walker O. Studies on Plasmodium falciparum parasitaemia and development of anaemia in Nigerian infants during their first year of life. Am. J. Trop. Med. Hyg. 1996, 55:138-143.
3. Achidi E.A., Salimou L.S., Perlmann H., Perlmann P., Berzins K., Williams A.I.O. Lack of association between levels of transplacentally acquired Plasmodium falciparum-specific antibodies and age of onset of clinical malaria in infants in a malaria endemic area of Nigeria. Acta Trop. 1996, 61:315-326.
4. Agnandij S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., Methogo B.G.N.O., Doucka Y., Flamen A., Mordmüller B., Issifou S., Kremsner P.G., Sacarlal J., Aide P., Lanaspa M., Aponte J.J., Nhamuave A., Quelhas D., Bassat Q., Mandjate S., Macete E., Alonso P., Abdulla S., Salim N., Juma O., Shomari M., Shubis K., Machera F., Hamad A.S., Minja R., Mtoro A., Sykes A., Ahmed S., Urassa A.M., Ali A.M., Mwangoka G., Tanner M., Tinto H., D'Alessandro U., Sorgho H., Valea I., Tahita M.C., Kaboré W., Ouédraogo S., Sandrine Y., Guiguemdé R.T., Ouédraogo J.B., Hamel M.J., Kariuki S., Odero C., Oneko M., Otieno K., Awino N., Omoto J., Williamson J., Muturi-Kioi V., Laserson K.F., Slutsker L., Otieno W., Otieno L., Nekoye O., Gondi S., Otieno A., Ogutu B., Wasuna R., Owira V., Jones D., Onyango A.A., Njuguna P., Chilengi R., Akoo P., Kerubo C., Gitaka J., Maingi C., Lang T., Olotu A., Tsofa B., Bejon P., Peshu N., Marsh K., Owusu-Agyei S., Asante K.P., Osei-Kwakye K., Boahen O., Ayamba S., Kayan K., Owusu-Ofori R., Dosoo D., Asante I., Adjei G., Adjei G., Chandramohan D., Greenwood B., Lusingu J., Gesase S., Malabeja A., Abdul O., Kilavo H., Mahende C., Liheluka E., Lemnge M., Theander T., Drakeley C., Ansong D., Agbenyega T., Adjei S., Boateng H.O., Rettig T., Bawa J., Sylverken J., Sambian D., Agyekum A., Owusu L., Martinson F., Hoffman I., Mvalo T., Kamthunzi P., Nkomo R., Msika A., Jumbe A., Chome N., Nyakuipa D., Chintedza J., Ballou W.R., Bruls M., Cohen J., Guerra Y., Jongert E., Lapierre D., Leach A., Lievens M., Ofori-Anyinam O., Vekemans J., Carter T., Leboulleux D., Loucq C., Radford A., Savarese B., Schellenberg D., Sillman M., Vansadia P. First results of phase 3 trials of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365:1863-1875. RTS,S Clinical Trials Partnership.
5. Aidoo M., Lalvani A., Allsopp C.E.M., Plebanski M., Meisner S.J., Krausa P., Browning M., Morris-Jones S., Gotch F., Fidock D.A., Takiguchi M., Robson K.J.H., Greenwood B.M., Druilhe P., Whittle H.C., Hill A.V.S. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995, 345:1003-1007.
6. Ambrosino E., Dumoulin C., Orlandi-Pradines E., Remoue F., Toure-Baldé A., Tall A., Sarr J.B., Poinsignon A., Sokhna C., Puget K., Trape J.F., Pascual A., Druilhe P., Fusai T., Rogier C. A multiplex assay for the simultaneous detection of antibodies against 15 Plasmodium falciparum and Anopheles gambiae saliva antigens. Malaria J. 2010, 9:317.
7. Aregawi M.W., Ali A.S., Al-Mafazy A.W., Molteni F., Katikiti S., Warsame M., Njau R.J., Komatsu R., Korenromp E., Hosseini M., Low-Deer D., Bjorkman A., D'Alessandro U., Coosemans M., Otten M. Reductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008. Malaria J. 2011, 10:46.
8. Bongfen S.E., Ntsama P.M., Offner S., Smith T., Felger I., Tanner M., Alonso P., Nebie I., Romero J.F., Silvie O., Torgler R., Corradin G. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 2009, 27:328-335.
9. Borrmann S., Matuschewski K. Targeting Plasmodium liver stages: better late than never. Trends Mol. Med. 2011, 17:527-536.
10. Bray R.S. Absence of circumsporozoite antibodies in areas of hyperendemic malaria. J. Parasitol. 1978, 64:410.
11. Brown A.E., Webster H.K., Tulyayon S., Suvarnamani A., Wirtz R.A., Sookto P. IgM antibody responses to the circumsporozoite protein in naturally acquired falciparum malaria. J. Clin. Immun. 1988, 8:342-348.
12. Bucci K., Kastens W., Hollingdale M.R., Shankar A., Alpers M.P., King C.L., Kazura J.W. Influence of age and HLA type on interferon-gamma (IFN-gamma) responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1 (LSA-1). Clin. Exp. Immunol. 2000, 122:94-100.
13. Burkot T.R., Graves P.M., Wirtz R.A., Brabin B.J., Battistutta D., Cattani J.A., Maizels R.M., Alpers M.P. Differential antibody responses to Plasmodium falciparum and P. vivax circumsporozoite proteins in a human population. J. Clin. Microbiol. 1989, 27:1346-1351.
14. Calle J.M., Nardin E.H., Clavijo P., Boudin C., Stüber D., Takacs B., Nussenzweig R.S., Cochrane A.H. Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers. J. Immunol. 1992, 149:2695-2701.
15. Campbell G.H., Brandling-Bennett A.D., Roberts J.M., Collins F.H., Kaseje D.C., Barber A.M., Tuner A. Detection of antibodies in human sera to the repeating epitope of the circumsporozoite protein of Plasmodium falciparum using the synthetic peptide (NANP)3 in an enzyme-linked immunosorbent assay (ELISA). Am. J. Trop. Med. Hyg. 1987, 37:17-21.
16. Campbell G.H., Collins F.H., Brandling-Bennett A.D., Schwartz I.K., Roberts J.M. Age-specific prevalence of antibody to a synthetic peptide of the circumsporozoite protein of Plasmodium falciparum in children from three villages in Kenya. Am. J. Trop. Med. Hyg. 1987, 37:220-224.
17. Campbell J.R., Paleologo F.R., Franke E.D., Ratiwayanto S., Hadiputranto H., Kurniawan L., Wistar R., Hoffman S.L., Annis B.A., Wasserman G., Laughlin L.W. Immune responses of humans to the circumsporozoite protein of Plasmodium falciparum: limited T cell response to the immunodominant central repeat region. Am. J. Trop. Med. Hyg. 1988, 39:232-235.
18. Ceesay S.J., Casals-Pascual C., Erskine J., Anya S.E., Duah N.O., Fulford A.J.C., Sesay S.S.S., Abubakar I., Dunya S., Sey O., Palmer A., Fofana M., Corrah T., Bojang K.A., Whittle H.C., Greenwood B.M., Conway D.J. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 2008, 372:1545-1554.
19. Charoenvit Y., Fallarme V., Rogers W.O., Sacci J.B., Kaur M., Aguiar J.C., Yuan L.F., Corradin G., Andersen E., Wizel B., Houghten R.A., Oloo A., de la Vega P., Hoffman S.L. Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Infect. Immun. 1997, 65:3430-3437.
20. Chelimo K., Ofulla A.V., Narum D.L., Kazura J.W., Lanar D.E., John C.C. Antibodies to Plasmodium falciparum antigens vary by age and antigen in children in a malaria-holoendemic area of Kenya. Pediatr. Infect. Dis. J. 2005, 24:680-684.
21. Chen D.H., Tigelaar R.E., Weinbaum F.I. Immunity to sporozoite-induced malaria infection in mice. I. The effect of immunization of T and B cell-deficient mice. J. Immunol. 1977, 118:1322-1327.
22. Chizzolini C., Delaporte E., Kaufmann M.H., Akue J.P., Verdini A.S., Pessi A., del Giudice G. Age-related prevalence of antibody response against three different, defined Plasmodium falciparum antigens in children from the Haut-Ogooué province in Gabon. Trans. R. Soc. Trop. Med. Hyg. 1989, 83:147-151.
23. Clyde D., Most H., McCarthy V., Vanderberg J. Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973, 266:169-177.
24. Cohen J., Nussenzweig V., Nussenzweig R., Vekemans J., Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Human Vaccines 2010, 6:90-96.
25. Connelly M., King C.L., Bucci K., Walters S., Genton B., Alpers M.P., Hollingdale M., Kazura J.W. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect. Immun. 1997, 65:5082-5087.
26. Coppi A., Pinzon-Ortis C., Hutter C., Sinnis P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J. Exp. Med. 2005, 201:27-33.
27. Coppi A., Natarajan R., Pradel G., Bennett B.L., James E.R., Roggero M.A., Corradin G., Persson C., Tewari R., Sinnis P. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 2011, 208:341-356.
28. Crompton P.D., Kayala M.A., Traore B., Kayentao K., Ongoiba A., Weiss G.E., Molina D.M., Burk C.R., Waisberg M., Jasinskas A., Tan X., Doumbo S., Doutambe D., Kone Y., Narum D.J., Liang X., Doumbo O.K., Miller L.H., Doolan D.L., Baldi P., Felgner P.L., Pierce S.K. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc. Natl. Acad. Sci. USA 2010, 107:6958-6963.
29. Dame J.B., Williams J.L., McCutchan T.F., Weber J.L., Wirtz R.A., Hockmeyer W.T., Maloy W.L., Heynes J.D., Scheider I., Roberts D., Sanders G.S., Reddy E.R., Diggs C.L., Miller L.H. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984, 225:593-599.
30. Daubersies P., Thomas A.W., Millet P., Brahimi K., Langermans J.A., Oliomo B., BenMohamed L., Slierendregt B., Eling W., Van Belkum A., Dubreuil G., Meis J.F., Guerin-Marchand C., Cayphas S., Cohen J., Gras-Masse H., Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med. 2000, 6:1258-1263.
31. Davies D.H., Liang X., Hernandez J.E., Randall A., Hirst S., Mu Y., Romero K.M., Nguyen T.T., Kalantari-Dehaghi M., Crotty S., Baldi P., Villareal L.P., Felgner P.L. High-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. USA 2005, 102:547-552.
32. De Groot A.S., Johnson A.H., Maloy W.L., Quakyi I.A., Riley E.M., Menon A., Banks S.M., Berzofsky J.A., Good M.F. Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein. J. Immunol. 1989, 142:4000-4005.
33. Del Giudice G., Verdini A.S., Pinori M., Pessi A., Verhave J.P., Tougne C., Ivanoff B., Lambert P.H., Engers H.D. Detection of human antibodies against Plasmodium falciparum sporozoites using synthetic peptides. J. Clin. Microbiol. 1987, 25:91-96.
34. Del Giudice G., Engers H.D., Tougne C., Biro S.S., Weiss N., Verdini A.S., Pessi A., Degremont A.A., Freyvogel T.A., Lambert P.H., Tanner M. Antibodies to the repetitive epitope of Plasmodium falciparum circumsporozoite protein in a rural Tanzanian community: A longitudinal study of 132 children. Am. J. Trop. Med. Hyg. 1987, 36:203-212.
35. Del Giudice G., Cheng Q., Mazier D., Berbiguier N., Cooper J.A., Engers H.D., Chizzolini C., Verdini A.S., Bonelli F., Pessi A., Lambert P.H. Immunogenicity of a non-repetitive sequence of Plasmodium falciparum circumsporozoite protein in man and mice. Immunology 1988, 63:187-191.
36. Del Giudice G., Lambert P.H., Mendis K., Pessi A., Tanner M. Antibody responses to Plasmodium falciparum and P. vivax sporozoites in areas with stable and unstable malaria. Bull. WHO 1990, 68(Suppl.):191-196.
37. Deloron P., Chougnet C., Lepers J.P., Tallet S., Colanges P. Protective value of elevated levels of gamma interferon in serum against exoerythrocytic stages of Plasmodium falciparum. J. Clin. Microbiol. 1991, 29:1757-1760.
38. Dolo A., Modiano D., Doumbo O., Bosman A., Sidibé T., Keita M.M., Naitza S., Robson K.J., Crisanti A. Thrombospondin related adhesive protein (TRAP), a potential malaria vaccine candidate. Parassitologia 1999, 41:425-428.
39. Doolan D.L., Houghten R.A., Good M.F. Location of human cytotoxic T cell epitopes within a polymorphic domain of the Plasmodium falciparum circumsporozoite protein. Int. Immunol. 1991, 3:511-516.
40. Doolan D.L., Khamboonruang C., Beck H.P., Houghten R.A., Good M.F. Cytotoxic T lymphocyte (CTL) low-responsiveness to the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: analysis of human CTL response to most known variants. Int. Immunol. 1993, 5:37-46.
41. Doolan D.L., Beck H.P., Good M.F. Evidence for limited activation of distinct CD4+ T cell subsets in response to the Plasmodium falciparum circumsporozoite protein in Papua New Guinea. Parasite Immunol. 1994, 16:129-136.
42. Doolan D.L., Southwood S., Chesnut R., Appella E., Gomez E., Richards A., Higashimoto Y.I., Maewal A., Sidney J., Gramzinski R.A., Mason C., Koech D., Hoffman S.L., Sette A. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 2000, 165:1123-1137.
43. Doolan D.L., Mu Y., Unal B., Sundaresh S., Hirst S., Valdez C., Randall A., Molina D., Liang X., Freilich D.A., Oloo J.A., Blair P.L., Aguiar J.C., Baldi P., Davies D.H., Felgner P.L. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008, 8:4680-4694.
44. Doolan D.L., Dobaño C., Baird J.K. Acquired immunity to malaria. Clin. Microb. Rev. 2009, 22:13-36.
45. Domarle O., Migot-Nabias F., Mvoukani J.L., Lu C.Y., Nabias R., Mayombo J., Tiga H., Deloron P. Factors influencing resistance to reinfection with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1999, 61:926-931.
46. Druilhe P., Pradier O., Marc J.-P., Miltgen F., Mazier D., Parent G. Levels of antibodies to Plasmodium falciparum sporozoite surface antigens reflect malaria transmission rates and are persistent in the absence of reinfection. Infect. Immun. 1986, 53:393-397.
47. Egan J.E., Weber J.L., Ballou W.R., Hollingdale M.R., Majarian W.R., Gordon D.M., Maloy W.L., Hoffman S.L., Wirtz R.A., Schneider I., Woollett G.R., Young J.F., Hockmeyer W.T. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 1987, 236:453-456.
48. Enea V., Ellis J., Zavala F., Arnot D.E., Asavanich A., Masuda A., Quakyi I., Nussenzweig R.S. DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 1984, 225:628-630.
49. Esposito F., Lombardi S., Modiano D., Zavala F., Reeme J., Lamizana L., Coluzzi M., Nussenzweig R.S. Immunity to Plasmodium sporozoites: recent advances and applications to field research. Parassitologia 1986, 28:101-105.
50. Esposito F., Lombardi S., Modiano D., Zavala F., Reeme J., Lamizana L., Coluzzi M., Nussenzweig R.S. Prevalence and levels of antibodies to the circumsporozoite protein of Plasmodium falciparum in an endemic area and their relationship to resistance against malaria infection. Trans. R. Soc. Trop. Med. Hyg. 1988, 82:827-832.
51. Esposito F., Lombardi S., Modiano D., Habluetzel A., Del Nero L., Lamizana L., Pietra V., Rotilgliano G., Corradin G., Ravot E., La Rosa C. In vitro immune recognition of synthetic peptides from the Plasmodium falciparum CS protein by individuals naturally exposed to different sporozoite challenge. Immunol. Lett. 1992, 33:187-199.
52. Ferreira-da-Cruz M.F., Deslandes D.C., Oliveira-Ferreira J., Montenegro-James S., Tartar A., Druilhe P., Daniel-Ribeiro C.T. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas. Parasite 1995, 2:23-29.
53. Fidock D.A., Gras-Masse H., Lepers J.P., Brahimi K., Benmohamed L., Mellouk S., Guerin-Marchand C., Londono A., Raharimalala L., Meis J.F.G.M., Langsley G., Roussilhon C., Tartar A., Druilhe P. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J. Immunol. 1994, 153:190-204.
54. Fidock D.A., Bottius E., Brahimi K., Moelans I.I., Aikawa M., Konings R.N., Certa U., Olafsson P., Kaidoh T., Asavinch A., Guerin-Marchand C., Druilhe P. Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP. Mol. Biol. Parasitol. 1994, 64:219-232.
55. Flanagan K.L., Plebanski M., Akinwunmi P., Lee E.A., Reece W.H., Robson K.J., Hill A.V., Pinder M. Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans. Eur. J. Immunol. 1999, 29:1943-1954.
56. Flanagan K.L., Mwangi T., Plebanski M., Odhiambo K., Ross A., Sheu, Kortok M., Lowe B., Marsh K., Hill A.V. Ex vivo interferon-gamma immune responses to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am. J. Trop. Med. Hyg. 2003, 68:421-430.
57. Flanagan K.L., Plebanski M., Odhiambo K., Sheu E., Mwangi T., Gelder C., Hart K., Kortok M., Lowe B., Robson K.J., Marsh K., Hill A.V.S. Cellular reactivity to the P. falciparum protein TRAP in adult Kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am. J. Trop. Med. Hyg. 2006, 74:367-375.
58. Gonzalez J.M., Peter K., Esposito F., Nebie I., Tiercy J.M., Bonelo A., Arevalo-Herrera M., Valmori D., Romero P., Herrera S., Corradin G., Lopez J.A. HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT. Parasite Immunol. 2000, 22:501-514.
59. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R., Heppner D.G., Yuan G., Hollingdale M.-., Slaoui M., Hauser P., Voet P., Sadoff J.C., Ballou W.R. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 1995, 171:1576-1585.
60. Good M.F., Maloy W.L., Lunde M.N., Margalit H., Cornette J.L., Smith G.L., Moss B., Miller L.H., Berzofsky J.A. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 1987, 235:1059-1062.
61. Good M.F., Pombo D., Quakyi I.A., Riley E.M., Houghten R.A., Menon A., Alling D.W., Berzofsky J.A., Miller L.H. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to polymorphic regions of the molecule. Proc. Natl. Acad. Sci USA 1988, 85:1199-1203.
62. Good M.F., Doolan D.L. Malaria vaccine design: immunological considerations. Immunity 2010, 33:555-566.
63. Greenhouse B., Ho B., Hubbard A., Njama-Meya D., Narum D.L., Lanar D.E., Dutta S., Rosenthal P.J., Dorsey G., John C.C. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J. Infect. Dis. 2011, 204:19-26.
64. Guerin-Marchand C., Druilhe P., Galey B., Londono A., Patarapotikul J., Beaudoin R.L., Dubeaux C., Tartar A., Mercereau-Puijalon O., Langsley G. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 1987, 329:164-167.
65. Hafalla J.C., Silvie O., Matuschewski K. Cell biology and immunology of malaria. Immunol. Rev. 2011, 240:297-316.
66. Hill A.V., Allsopp C.E., Kwiatkowski D., Anstey N.M., Twumasi P., Rowe P.A., Bennett S., Brewster D., McMichael A.J., Greenwood B.M. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991, 352:595-600.
67. Hill A.V.S., Elvin J., Willis A.C., Aidoo M., Allsopp C.E.M., Gotch F.M., Gao X.M., Takiguchis M., Greenwood B.M., Townsend A.I.R.M., McMichael A.J., Whittle H.C. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992, 360:434-439.
68. Hill A.V. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 2006, 6:21-32.
69. Hoffman S.L., Wislar R., Ballou W.R., Hollingdale M.R., Wirtz R.A., Schneider I., Marwoto H.A., Hockmeyer W.T. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. New Engl. J. Med. 1986, 315:601-606.
70. Hoffman S.L., Oster C.N., Plowe C.V., Woollett G.R., Beier J.C., Chulay J.D., Wirtz R.A., Hollingdale M.R., Mugambi M. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 1987, 237:639-642.
71. Hoffman S.L., Oster C.N., Mason C., Beier J.C., Sherwood J.A., Ballou W.R., Mugambi M., Chulay J.D. Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. J. Immunol. 1989, 142:1299-1303.
72. Hogh B., Marbiah N.T., Petersen E., Perlmann H., Dolopaye E., Hanson A.P., Bjorkman A., Perlmann P. A longitudinal study of seroreactivities to Plasmodium falciparum antigens in infants and children living in a holoendemic area of Liberia. Am. J. Trop. Med. Hyg. 1991, 44:191-200.
73. Hollingdale M.R., Nardin E.H., Tharavanij S., Schwartz A.L., Nussenzweig R.S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 1984, 132:909-913.
74. Hollingdale M.R., Hogh B., Petersen E., Wirtz R.A., Bjorkmann A. Age-dependent occurrence of protective anti-Plasmodium falciparum sporozoite antibodies in a holoendemic area of Liberia. Trans. R. Soc. Med. Hyg. 1989, 83:322-324.
75. Hope I.A., Hall R., Simmons D.L., Hyde J.E., Scaife J.G. Evidence for immunological cross-reaction between sporozoites and blood stages of a human malaria parasite. Nature 1984, 308:191-194.
76. John C.C., Sumba P.O., Ouma J.H., Nahlen B.L., King C.L., Kazura J.W. Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya. Infect. Immun. 2000, 68:5198-5204.
77. John C.C., Zickafoose J.S., Sumba P.O., King C.I., Kazura J.W. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adjhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in highland Kenya. Infect. Immun. 2003, 71:4320-4325.
78. John C.C., Moormann A.M., Pregibon D.C., Sumba P.O., McHugh M.M., Narum D.L., Lanar D.E., Schluchter M.D., Kazura J.W. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am. J. Trop. Med. Hyg. 2005, 73:222-228.
79. John C.C., Tande A.J., Moormann A.M., Sumba P.O., Lanar D.E., Min X.M., Kazura J.W. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J. Infect. Dis. 2008, 197:519-526.
80. The level of anti-sporozoite antibodies in a highly endemic area and its relationship with exposure to mosquitoes. Trans. R. Soc. Trop. Med. Hyg. 1992, 86:499-504. Kilombero Malaria Project.
81. Kitua A.Y., Urassa H., Wechsler M., Smith T., Vounatsou P., Weiss N.A., Alonso P.L., Tanner M. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationship with clinical malaria and with entomological inoculation rates. Parasite Immunol. 1999, 21:307-317.
82. Kleinschmidt I., Schwabe C., Benavente L., Torrez M., Ridl F.C., Segura J.L., Ehmer P., Nchama G.N. Marked increase in child survival after four years of intensive malaria control. Am. J. Trop. Med. Hyg. 2009, 80:882-888.
83. Koch R. Dritter Bericht über die Tätigkeit der Malariaexpedition. Dtsch. Med. Wochenschr. 1900, 26:281-284.
84. Kurtis J.D., Lanar D.E., Opollo M., Duffy P.E. Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect. Immun. 1999, 67:3424-3429.
85. Kurtis J.D., Hollingdale M.R., Luty A.J., Lanar D.E., Krzych U., Duffy P.E. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol. 2001, 17:219-223.
86. Lalvani A., Hurt N., Aidoo M., Kibatala P., Tanner M., Hill A.V. Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. Eur. J. Immunol. 1996, 26:773-779.
87. Langhorne J., Ndungu F.M., Sponaas A.M., Marsh K. Immunity to malaria: more questions than answers. Nat. Immunol. 2008, 9:725-732.
88. Lopez J.A., Roggero M.A., Duombo O., Gonzalez J.M., Tolle R., Koita O., Arevalo-Herrera M., Herrera S., Corradin G. Recognition of synthetic 104-mer and 102-mer peptides corresponding to the N- and C- terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors. Am. J. Trop. Med. Hyg. 1996, 55:424-429.
89. Luty A.J., Lell B., Schmidt-Ott R., Lehman L.G., Luckner D., Greve B., Matousek P., Herbich K., Schmid D., Ulbert S., Migot-Nabias F., Dubois B., Deloron P., Kremsner P.G. Parasite antigen-specific interleukin-10 and antibody responses predict accelerated parasite clearance in Plasmodium falciparum malaria. Eur. Cytokine Netw. 1998, 9:639-646.
90. Luty A.J., Lell B., Schmidt-Ott R., Lehman L.G., Luckner D., Greve B., Matousek P., Herbich K., Schmid D., Migot-Nabias F., Deloron P., Nussenzweig R.S., Kremsner P.G. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 1999, 179:980-988.
91. Luty A., Bongartz M., Rezbach P., Faucher J.F., Hollingdale M.R., Kremsner P.G. Plasmodium falciparum liver-stage antigen-1 peptide-specific interferon-gamma responses are not suppressed during uncomplicated malaria in African children. Eur. Cytokine Netw. 2001, 12:647-653.
92. Marsh K., Hayes R.H., Carson D.C., Otoo L., Shenton F., Byass P., Zavala F., Greenwood B.M. Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population. Trans. R. S. Trop. Med. Hyg. 1988, 82:532-537.
93. Marsh K., Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006, 28:51-60.
94. Matuschewski K. Vaccine development against malaria. Curr. Opin. Immunol. 2006, 18:449-457.
95. Mellouk S., Mazier D., Druilhe P., Berbiguier N., Danis M. In vitro and in vivo results suggesting that anti-sporozoite antibodies do not totally block Plasmodium falciparum infectivity. New Engl. J. Med. 1986, 315:648.
96. Meraldi V., Nebie I., Moret R., Cuzin-Ouattara N., Thiocone A., Doumbo O., Esposito F., Traore A.S., Corradin G., Terenzi S. Recognition of synthetic polypeptides corresponding to the N- and C-terminal fragments of Plasmodium falciparum Exp-1 by T-cells and plasma from human donors from African endemic areas. Parasite Immunol. 2002, 24:141-150.
97. Migot-Nabias F., Deloron P., Ringwald P., Dubois B., Mayombo J., Minh T.N., Fievet N., Millet P., Luty A. Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans. R. Soc. Trop. Med. Hyg. 2000, 94:557-562.
98. Moyano E.M., Gonzalez L.M., Arahuetes S., Benito A. Liver stage antigen 3 isolated from a cDNA library of Plasmodium falciparum erythrocytic stages. Parasitol. Res. 2007, 102:111-115.
99. Murray C.J.L., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., Fullman N., Naghavi M., Lozano R., Lopez A.D. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.
100. Nardin E.H., Nussenzweig R.S., McGregor I.A., Bryan J.H. Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science 1979, 206:597-599.
101. Nardin E.H., Nussenzweig R.S., Bryan J.H., McGregor I.A. Congenital transfer of antibodies against malarial sporozoites detected in Gambian infants. Am. J. Trop. Med. Hyg. 1981, 30:1159-1163.
102. Nguyen T., Fujioka H., Kang A., Rogers W., Fidock D., James A. Stage-dependent localization of a novel gene product of the malaria parasite, Plasmodium falciparum. J. Biol. Chem. 2001, 276:26724-26731.
103. Nguyen T., Sacci J., de la Vega P., John C.C., James A., Kang A. Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals. Malar. J. 2009, 8:235.
104. Noland G.S., Hendel-Paterson B., Min X.M., Moormann A.M., Vulule J.M., Narum D.L., Lanar D.E., Kazura J.W., John C.C. Low prevalence of antibodies to preerythrocytic but not blood stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission. Infect. Immun. 2008, 76:5721-5728.
105. Nussenzweig V., Nussenzweig R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 1989, 45:283-334.
106. Olotu A.I., Fegan G., Bejon P. Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naïve adults. J. Infect. Dis. 2010, 201:970-971.
107. Olotu A., Lusingu J., Leach A., Lievens M., Vekemans J., Msham S., Lang T., Gould J., Dubois M.C., Jongert E., Vansadia P., Carter T., Niuguna P., Awundo K.O., Malabeia A., Abdul O., Gesase S., Mturi N., Drakeley C.J., Savarese B., Vilafana T., Lapierre D., Ballou W.R., Cohen J., Lemnge M.M., Peshu N., Marsh K., Riley E.M., von Seidlein L., Bejon P. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis of anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomized controlled trial. Lancet Infect. Dis. 2011, 11:102-109.
108. O'Meara W.P., Bejon P., Mwangi T.W.M., Okiro E.A., Peshu N., Snow R.W., Newton C.R.J.C., Marsh K. Effect of fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008, 372:1555-1562.
109. Ong'echa J.M., Lal A.A., Terlouw D.J., Ter Kuile F.O., Kariuki S.K., Udhayakumar V., Orago A.S., Hightower A.W., Nahlen B.L., Shin Y.P. Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Aembo Bay Cohort Project. Am. J. Trop. Med. Hyg. 2003, 68:590-597.
110. Pasquetto V., Fidock D.A., Gras H., Badell E., Eling W., Ballou W.R., Belghiti J., Tartar A., Druilhe P. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen. Eur. J. Immunol. 1997, 27:2502-2513.
111. Plebanski M., Aidoo M., Whittle H.C., Hill A.V. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J. Immunol. 1997, 158:2849-2855.
112. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., Plebanski M., Akinwunmi P., Everaere S., Watkins K.R., Voss G., Tornieporth N., Alloueche A., Greenwood B.M., Kester K.E., McAdam K.P., Cohen J., Hill A.V. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 2004, 10:406-410.
113. Riley E.M., Allen S.J., Bennett S., Thomas P.J., O'Donell A., Lindsay S.W., Good M.F., Greenwood B.M. Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:648-657.
114. Robson K.J.H., Hall J.R.S., Jennings M.W., Harris T.J.R., Marsh K., Newbold C.I., Tate V.E., Weatherall D.J. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988, 355:79-82.
115. Sacarlal J., Aide P., Aponte J.J., Renom M., Leach A., Mandomando I., Lievens M., Bassat Q., Lafuente S., Macete E., Vekemans J., Guinovart C., Sigaúque B., Sillman M., Milman J., Dubois M.C., Demoitié M.A., Thonnard J., Menéndez C., Ballou W.R., Cohen J., Alonso P.L. Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 2009, 200:329-336.
116. Sanchez G.I., Rogers W.O., Mellouk S., Hoffman S.L. Plasmodium falciparum: exported protein-1, a blood stage antigen, is expressed in liver stage parasites. Exp. Parasitol. 1994, 79:59-62.
117. Scarselli E., Tolle R., Koita O., Diallo M., Müller H.M., Früh K., Doumbo O., Crisanti A., Bujard H. Analysis of the human antibody response to thrombospondin-related anonymous protein of Plasmodium falciparum. Infect. Immun. 1993, 61:3490-3495.
118. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 330:664-666.
119. Schofield L. The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite?. Bull. WHO 1990, 68(Suppl):66-73.
120. Schwenk R.J., Richie T.L. Protective immunity to pre-erythrocytic stage malaria. Trends Parasitol. 2011, 27:306-314.
121. Sedegah M., Sim B.K., Mason C., Nutman T., Malik A., Roberts C., Johnson A., Ochola J., Koech D., Were B. Naturally acquired CD8+ cytotoxic T lymphocytes against Plasmodium falciparum circumsporozoite protein. J. Immunol. 1992, 149:966-971.
122. Sharma P., Bharadwaj A., Bhasin V.K., Sallaja V.N., Chauhan V.S. Antibodies to a conserved-motif peptide sequence of the Plasmodium falciparum thrombospondin-related anonymous protein and circumsporozoite protein recognize a 78-kilodalton protein in the asexual blood stages of the parasite and inhibit merozoite invasion in vitro. Infect. Immun. 1996, 64:2172-2179.
123. Shi Y.P., Udhayakumar V., Alpers M.P., Povoa M.M., Oloo A.J., Ruebush T.K., Lal A.A. Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum cicrumsporozoite protein. Infect. Immun. 1993, 61:2425-2433.
124. Silvie O., Franetich J.F., Charrin S., Mueller M.S., Siau A., Bodescot M., Rubinstein E., Hannoun L., Charoenvit Y., Kocken C.H., Thomas A.W., Van Gemert G.J., Sauerwein R.W., Blackman M.J., Anders R.F., Pluschke G., Mazier D. A role for the apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. 2004, 279:9490-9496.
125. Silvie O., Mota M.M., Matuschewski K., Prudêncio M. Interactions of the malaria parasite and its mammalian host. Curr. Opin. Microbiol. 2008, 11:352-359.
126. Sinigaglia F., Guttinger M., Gillessen D., Doran D.M., Takacs B., Matile H., Trzeciak A., Pink J.R. Epitopes recognized by human T lymphocytes on malaria circumsporozoite protein. Eur. J. Immunol. 1988, 18:633-636.
127. Sinigaglia F., Guttinger M., Kilgus J., Doran D.M., Matile H., Etlinger H., Trzeciak A., Gillessen D., Pink J.R.L. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988, 336:778-780.
128. Smith T., Maire N., Dietz K., Killeen G.F., Vounatsou P., Molineaux L., Tanner M. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 2006, 75:11-18.
129. Struik S.S., Riley E.M. Does malaria suffer from lack of memory?. Immunol. Rev. 2004, 201:268-290.
130. Stüber D., Bannwarth W., Pink J.R., Meloen R.H., Matile H. New B cell epitopes in the Plasmodium falciparum malaria circumsporozoite protein. Eur. J. Immunol. 1990, 20:819-824.
131. Suwancharoen C., Putaporntip C., Rungruang T., Jongwutiwes S. Naturally acquired IgG antibodies against the C-terminal part of Plasmodium falciparum sporozoite threonine-asparagine-rich protein in a low endemic area. Parasitol. Res. 2011, 109:315-320.
132. Tall A., Sokhna C., Perrault R., Fontenille D., Marrama L., Ly A.B., Sarr F.D., Toure A., Trape J.-F., Spiegel A., Rogier C., Druilhe P. Assessment of the relative success of sporozoite inoculations in individuals exposed to moderate seasonal transmission. Malaria J. 2009, 8:161.
133. Tapchaisri P., Chomcharn Y., Poonthong C., Asavanich A., Limsuwan S., Maleevan O., Tharavanij S., Harinasuta T. Anti-sporozoite antibodies induced by natural infection. Am. J. Trop. Med. Hyg. 1983, 32:1203-1208.
134. Todryk S.M., Bejon P., Mwangi T., Plebanski M., Urban B., Marsh K., Hill A.V., Flanagan K.L. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS ONE 2008, 3:e2027.
135. Toure-Balde A., Perlaza B.L., Sauzet J.P., Ndiaye M., Aribot G., Tall A., Sokhna C., Rogier C., Corradin G., Roussilhon C., Druilhe P. Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3. Infect. Immun. 2009, 77:1189-1196.
136. Trape J.F., Rogier C. Combating malaria morbidity and mortality by reducing transmission. Parasitol. Today 1996, 12:236-240.
137. Webster H.K., Ho M., Looareesuwan S., Pavanand K., Wattanagoon Y., Warrell D.A., Hockmeyer W.T. Lymphocyte responsiveness to a candidate malaria sporozoite vaccine (R32tet32) of individuals with naturally acquired Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 1988, 38:37-41.
138. Wijesundera M., de S., Peiris J.S.M., Ariyaratne Y.G., Verdini A.S., Pessi A., Del Giudice G. Antibodies to Plasmodium falciparum sporozoites following a malarial outbreak in a non-endemic area of Sri Lanka. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:35-39.
139. WHO, 2011. World Malaria Report 2011. World Health Organization, Switzerland. <>. http://www.who.int/malaria/world_malaria_report_2011/en/index.html.
140. Zavala F., Cochrane A.H., Nardin E.H., Nussenzweig R.S., Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J. Exp. Med. 1983, 157:1947-1957.
141. Zavala F., Tam J.P., Hollingdale M.R., Cochrane A.H., Quakyi I., Nussenzweig R.S., Nussenzweig V. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 1985, 228:1436-1449.
142. Zavala F., Tam J.P., Masuda A. Synthetic peptides as antigens for the detection of humoral immunity to Plasmodium falciparum sporozoites. J. Immunol. Methods 1986, 93:55-61.
143. Zevering Y., Houghten R.A., Frazer I.H., Good M.F. Major population differences in T cell response to a malaria sporozoite vaccine candidate. Int. Immunol. 1990, 2:945-955.
144. Zevering Y., Khamboonruang C., Rungruengthanakit K., Tungviboonchai L., Ruengpipattanapan J., Bathurst I., Barr P., Good M.F. Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc. Natl. Acad. Sci. USA 1994, 91:6118-6122.
145. Zhou Z., Xiao L., Branch O.H., Kariuki S., Nahlen B.L., Lal A.A. Antibody responses to the repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of Western Kenya. XIII. Asembo Bay Cohort Project. Am. J. Trop. Med. Hyg. 2002, 66:7-12.
146. Zhu J., Hollingdale M.R. Structure of the Plasmodium falciparum liver stage antigen 1. Mol. Biochem. Parasitol. 1991, 48:223-226.